Bisantrene (CS1, NSC-337766, CL 216,942) is an anthracene derivative with anti-tumor activity and a potent and selective FTO inhibitor.
research use only
Cat.No.S9946
|
In vitro |
0.1MHCl : 15 mg/mL
DMSO
: 3 mg/mL
(7.52 mM)
Warmed with 50°C water bath;
Ultrasonicated;
Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 398.46 | Formula | C22H22N8 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 78186-34-2 | -- | Storage of Stock Solutions |
|
|
| Targets/IC50/Ki |
FTO
|
References |
|---|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06084533 | Enrolling by invitation | Parkinson Disease |
Washington University School of Medicine |
January 10 2024 | -- |
| NCT06129838 | Recruiting | Alzheimer Disease |
Washington University School of Medicine |
May 5 2023 | -- |
| NCT04517552 | Active not recruiting | Alzheimer Disease |
Tammie L. S. Benzinger MD PhD|Washington University School of Medicine |
November 2 2020 | -- |
| NCT04142619 | Terminated | Relapsed/Refractory Multiple Myeloma |
Cellectis S.A. |
November 21 2019 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.